Clinical efficacy of semaglutide in patients with non-proliferative diabetic retinopathy
Huang Hai
Sun Qin
Tang Yi-quan
Abstract：Objective To investigate the efficacy of semaglutide combined with calcium dobesilate for the treatment of pa-tients with non-proliferative diabetic retinopathy (NPDR). Methods A total of 86 NPDR patients admitted to Hai'an People's Hospital from July 2021 to March 2023 were divided into two groups using the random number table method. The patients in the control group (n=43) were given calcium dobesilate while those in the observation group (n=43) were given semaglutide based on the regimen in the control group. The clinical efficacy,fasting blood glucose (FBG),glycosylated hemoglobin (HbA1c),best correct-ed visual acuity (BCVA),central retinal thickness (CRT),visual field gray value,hemangioma volume and bleeding spot area before and after treatment were compared between the two groups. Results The effective rate in the observation group was 90.69％ (39/43),which was higher than that of 72.09％ in the control (31/43) (x2=4.917,P<0.05). After treatment,FBG and HbAlc were significantly lower in the observation group than in the control ((7.12±1.69) mmol·L-1 vs (8.34±1.73) mmol·L-1,(6.22±1.07)％ vs (7.31±1.28)％) (t=3.307,4.284,P<0.05). BCVA was higher in the observation group than in the control ((0.62±0.12) vs (0.51±0.11)). The levels of CRT,visual field gray value,hemangioma volume,and bleeding spot area were (308.19±23.07) μm,(1.47±0.46)％,(11.19±2.07) μm3,(1.24±0.20) mm2 in the observation group,which were remarkably lower than those of (334.31±22.48) μm,(2.28±0.73)％,(14.31±2.48) μm3,(1.78±0.26) mm2 in the control (t=4.431,5.317,6.155,6.333,10.749,P<0.05). There was no significant difference in the adverse reaction rate between the two groups (11.62％ (5/43) vs 4.65％ (2/43),x2=0.622,P<0.05). Conclusion Semaglutide combined with calcium dobesilate has significant efficacy in the treatment of patients with NPDR. It can effectively enhance blood sugar control,promote the repair of fundus lesions,control the progression of lesions,improve the visual function of patients,and has good safety.
Keywords：SemaglutideCalcium dobesilateNon-proliferative diabetic retinopathyClinical efficacyGlucagon-like peptide-1 receptor agonist
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 817-820 )